Evidence map›Paper›PMID 25827088›Full record

ArticleCurrent protocols in molecular biology2015

Site-specific recombinational cloning using gateway and in-fusion cloning schemes.

Jaehong Park, Andrea L Throop, Joshua LaBaer

Open access · greenAbstract read
In one paragraph

Article in Current protocols in molecular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Unveiling the dimer/monomer propensities of Smad MH1-DNA complexes.Computational and structural biotechnology journal · 2021
    Article
  8. Isolation of Monoclonal Antibodies from Zika Virus-Infected Patient Samples.Methods in molecular biology (Clifton, N.J.) · 2020
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jaehong ParkHarvard Medical School, Cambridge, Massachusetts.
Andrea L ThroopBiodesign Institute, Arizona State University, Tempe, Arizona.
Joshua LaBaerHarvard Medical School, Cambridge, Massachusetts.
Arizona State University · USHarvard University · US

Funding

Contiunation and Enhancement of the PSI: Biology-Materials RepositoryU01GM098912 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI LABAER, JOSHUA · 2011 to 2015
$6.9M
NIGMS NIH HHS U01 GM098912
6 · The paper itself

Abstract

The comprehensive study of protein structure and function, or proteomics, depends on the obtainability of full-length cDNAs in species-specific expression vectors and subsequent functional analysis of the expressed protein. Recombinational cloning is a universal cloning technique based on site-specific recombination that is independent of the insert DNA sequence of interest, which differentiates it from classical restriction enzyme-based cloning methods. Recombinational cloning enables rapid and efficient parallel transfer of DNA inserts into multiple expression systems. This unit summarizes strategies for generating expression-ready clones using the most popular commercial recombinational cloning technologies, Gateway (Life Technologies) and In-Fusion (Clontech).

Indexed as

Recombination, GeneticCloning, MolecularRecombinant ProteinsRecombinant ProteinsCre-LoxGatewayhigh-throughputIn-Fusionrecombinational cloning

Identifiers

PMID25827088
PMCPMC4492480
OpenAlexW1480883620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.